ArleneO.Siefker-RadtkeMD

Oncology • Houston, TX

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Genitourinary Medical Oncology

Join to view full profile

Dr. Siefker-Radtke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Siefker-Radtke's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2001 - 2024
OK State Medical License 2020 - 2021

Clinical Trials

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Dec 01
Terminated
Phase 2
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone Start of enrollment: 2003 Mar 20
Completed
Phase 1
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Start of enrollment: 2003 Apr 23
Active, not recruiting
Phase 2
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer Start of enrollment: 2004 Feb 01
Terminated
Phase 2
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Start of enrollment: 2006 Sep 28
Active, not recruiting
Phase 1
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 2
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Start of enrollment: 2008 Jun 10
Completed
Phase 2
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors Start of enrollment: 2012 Jan 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
Fleming, S., Gifkins, D., Resnick, H., Rosenberg, P., Gaj, C., Maio, V., Crawford, A., Lu-Yao, G., Shalaby, W., Gao, J., Siefker-Radtke, A.> ;Clinical Genitourinary Cancer. 2024 Feb 15
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel, P., Sweis, R., Bupathi, M., Heath, E., Goodman, O., Hoimes, C., Milowsky, M., Davis, N., Kalebasty, A., Picus, J., Shaffer, D., Mao, S., Adra, N., Yorio, J., ...> ;European Urology Oncology. 2023 Dec 16
Evolution of front-line immunotherapy for metastatic urothelial cancer.
Siefker-Radtke, A., Desai, M.> ;The Lancet. Oncology. 2024 Jan 1
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center...
Jan K Rudzinski, Craig V Labbate, Patrick J Hensley, Kelly K Bree, Charles C Guo, Omar Alhalabi, Matthew T Campbell, Arlene O Siefker-Radtke, Neema Navai, Colin P N Di...> ;The Journal of Urology. 2024 Feb 1
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Yohann Loriot, Anne O'Hagan, Arlene O Siefker-Radtke> ;Future Oncology. 2024 Feb 1
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Omar Alhalabi, Nathaniel Wilson, Lianchun Xiao, Yiyun Lin, Jaanki Khandelwal, Mohammad Jad Moussa, Pavlos Msaouel, Neema Navai, Jianjun Gao, Ashish M Kamat, Patrick Pi...> ;European Urology Oncology. 2023 Dec 1
1 citations
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, Arlene O Siefker-Radtke, Jakub Zolnierek, Tibor Csoszi, Sang Joon Shin, Se Hoon Park, Vagif Atduev, Mahmut Gumus,...> ;European Urology. 2024 Mar 1
1 citations
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
Arlene O Siefker-Radtke, Diana Cauley, Omar Alhalabi> ;Journal of Clinical Oncology. 2023 Sep 1
2 citations
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Siefker-Radtke, A., Necchi, A., Park, S., García-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh Kalebasty, A., Mellado, B., Varlamov, S., Joshi, M., Duran...> ;European Urology Open Science. 2023 Apr 1
2 citations
Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An ...
Arash Rezazadeh Kalebasty, David J Benjamin, Yohann Loriot, Dimitrios Papantoniou, Arlene O Siefker-Radtke, Andrea Necchi, Vahid Naini, Jenna Cody Carcione, Ademi Sant...> ;European Urology Open Science. 2023 Jan 1
5 citations
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal...> ;European Urology. 2022 Oct 1
1 citations
Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
Craig V Labbate, Patrick J Hensley, Tanner S Miest, Wei Qiao, Mehrad Adibi, Amishi Y Shah, Lisly Chery, John Papadopoulos, Arlene O Siefker-Radtke, Jianjun Gao, Charle...> ;Urologic Oncology. 2022 Oct 1
8 citations
Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Jenny Peng, Srikala Sridhar, Arlene Odelia Siefker-Radtke, Shamini Selvarajah, Di Maria Jiang> ;Current Treatment Options in Oncology. 2022 Sep 1
Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.
Michael P Zaleski, Hui Chen, Sinchita Roy-Chowdhuri, Keyur P Patel, Rajyalakshmi Luthra, Mark J Routbort, Ashish M Kamat, Jianjun Gao, Arlene Siefker-Radtke, Bogdan Cz...> ;American Journal of Clinical Pathology. 2022 Aug 4
85 citations
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Thomas W Flaig, Philippe E Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Rich...> ;Journal of the National Comprehensive Cancer Network. 2022 Aug 1
Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Arlene O Siefker-Radtke, Yohann Loriot> ;American Journal of Health-System Pharmacy. 2022 May 24
17 citations
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Alhalabi, O., Chen, J., Zhang, Y., Lu, Y., Wang, Q., Ramachandran, S., Tidwell, R., Han, G., Yan, X., Meng, J., Wang, R., Hoang, A., Wang, W., Song, J., Lopez, L., And...> ;Nature Communications. 2022 Apr 4
10 citations
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhur...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
4 citations
Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.
Mehrad Adibi, Barrett McCormick, Minas P Economides, Firas Petros, Lianchun Xiao, Charles Guo, Amishi Shah, Ashish M Kamat, Colin Dinney, Neema Navai, Jianjun Gao, Arl...> ;Clinical Genitourinary Cancer. 2022 Apr 1
53 citations
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle F Burgess, Mark T Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado,...> ;The Lancet. Oncology. 2022 Feb 1
2 citations
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.
Omar Alhalabi, Matthew T Campbell, Lianchun Xiao, Ana C Adriazola, Nathaniel R Wilson, Arlene O Siefker-Radtke, Paul G Corn, Amado Zurita, Eric Jonasch, Jianjun Gao, M...> ;BJUI Compass. 2022 Jan 1
13 citations
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
Omar Alhalabi, Yueting Zhu, Ameer Hamza, Wei Qiao, Yiyun Lin, Raymond M. Wang, Amishi Yogesh Shah, Matthew T. Campbell, Vijaykumar Holla, Ashish M. Kamat, Wei-Lien Wan...> ;European Urology Oncology. 2021 Nov 14
Reply by Authors.
Patrick J Hensley, Kelly K Bree, Matthew T Campbell, Omar Alhalabi, Andrea Kokorovic, Tanner Miest, Graciela M Nogueras-Gonzalez, Jianjun Gao, Arlene O Siefker-Radtke,...> ;The Journal of Urology. 2021 Nov 1
66 citations
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Zin Thein, Benjamin S. Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang, Minghao Dang, Enyu Dai, S...> ;Nature Communications. 2021 Sep 23
11 citations
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.
Pavlos Msaouel, Clara Oromendia, Arlene O. Siefker-Radtke, Nizar M. Tannir, Sumit K. Subudhi, Jianjun Gao, Yinghong Wang, Bilal A. Siddiqui, Amishi Yogesh Shah, Ana Ap...> ;JAMA Network Open. 2021 Aug 2
Join now to see all

Lectures

Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
2019 ASCO Annual Meeting - 6/1/2019
FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary anal...
2019 ASCO Annual Meeting - 6/1/2019
Tailoring of Chemotherapy to Fit Patients With Metastatic Urothelial Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelia...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023
Can Frequent UTIs Be a Sign of Bladder Cancer?March 9th, 2023
Neoadjuvant Chemotherapy Shows “Clear Benefit” in Upper Tract Urothelial CarcinomaJanuary 26th, 2023
Join now to see all